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Native, Intact Glucagon-Like Peptide 1 Is a 
Natural Suppressor of Thrombus Growth Under 
Physiological Flow Conditions
Marieke Sternkopf,* Magdolna Nagy,* Constance C.F.M.J. Baaten,* Marijke J.E. Kuijpers, Bibian M.E. Tullemans, Julia Wirth,  
Wendy Theelen, Tom G. Mastenbroek, Michael Lehrke, Benjamin Winnerling, Lesley Baerts, Nikolaus Marx,  
Ingrid De Meester, Yvonne Döring, Judith M.E.M. Cosemans, Andreas Daiber, Sebastian Steven, Joachim Jankowski,  
Johan W.M. Heemskerk, Heidi Noels
OBJECTIVE: In patients with diabetes mellitus, increased platelet reactivity predicts cardiac events. Limited evidence suggests that DPP-
4 (dipeptidyl peptidase 4) influences platelets via GLP-1 (glucagon-like peptide 1)-dependent effects. Because DPP-4 inhibitors 
are frequently used in diabetes mellitus to improve the GLP-1-regulated glucose metabolism, we characterized the role of DPP-4 
inhibition and of native intact versus DPP-4-cleaved GLP-1 on flow-dependent thrombus formation in mouse and human blood.
APPROACH AND RESULTS: An ex vivo whole blood microfluidics model was applied to approach in vivo thrombosis and study 
collagen-dependent platelet adhesion, activation, and thrombus formation under shear-flow conditions by multiparameter 
analyses. In mice, in vivo inhibition or genetic deficiency of DPP-4 (Dpp4−/−), but not of GLP-1-receptors (Glp1r−/−), suppressed 
flow-dependent platelet aggregation. In human blood, GLP-1(7-36), but not DPP-4-cleaved GLP-1(9-36), reduced thrombus 
volume by 32% and impaired whole blood thrombus formation at both low/venous and high/arterial wall-shear rates. These 
effects were enforced upon ADP costimulation and occurred independently of plasma factors and leukocytes. Human 
platelets did not contain detectable levels of GLP-1-receptor transcripts. Also, GLP-1(7-36) did not inhibit collagen-induced 
aggregation under conditions of stirring or stasis of platelets, pointing to a marked flow-dependent role.
CONCLUSIONS: Native, intact GLP-1 is a natural suppressor of thrombus growth under physiological flow conditions, with 
DPP-4 inhibition and increased intact GLP-1 suppressing platelet aggregation under flow without a main relevance of GLP-
1-receptor on platelets.
VISUAL OVERVIEW: An online visual overview is available for this article.
Key Words: diabetes mellitus ◼ dipeptidyl peptidase 4 ◼ glucagon-like peptide 1 ◼ glucose ◼ platelets
DPP (dipeptidyl peptidases) consists of a family of intracellular or extracellular exopeptidases that cleave X-proline dipeptides from the polypeptide N terminus. 
Since DPP-4 (dipeptidyl peptidase 4 or CD26) cleaves 
the incretin hormone GLP-1 (glucagon-like peptide 1) and 
thereby regulates glucose metabolism,1 this enzyme has 
been highly investigated in the context of type 2 diabetes 
mellitus. Enhanced secretion of GLP-1 on food uptake 
activates the GLP-1R (GLP-1 receptor) on pancreatic β 
cells, triggering insulin release and consequently reducing 
blood glucose level. DPP-4 rapidly cleaves the native intact 
GLP-1 forms, that is, GLP-1(7-36) amide and GLP-1(7-
37), into GLP-1(9-36) amide and GLP-1(9-37), respec-
tively, both of which are incapable of stimulating GLP-1R.2 
Accordingly, inhibitors of DPP-4, such as linagliptin and 
sitagliptin, markedly prolong the half-life of native GLP-1 
and are being successfully applied to reduce hyperglyce-
mia in patients with diabetes mellitus.1,3
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Patients with diabetes mellitus have a 2- to 4-fold 
higher risk to develop cardiovascular diseases and, at 
least in some studies, encounter a mortality rate as high 
as patients with a previous myocardial infarction.4,5 In dia-
betes mellitus, increased platelet reactivity was found to be 
a strong independent predictor of major adverse cardiac 
events.5,6 In line with platelet hyperactivity, diabetes melli-
tus is also associated with increased atherosclerosis and 
thrombosis as underlying pathologies of cardiovascular 
disease.7–9 Antiplatelet therapy in patients with diabetes 
mellitus has proven to be beneficial for secondary preven-
tion of atherothrombotic recurrences10 and can also reduce 
vascular events in the absence of cardiovascular disease.11
First indications that DPP-4 activity can affect platelet 
activation came from a study revealing that platelets from 
patients with diabetes mellitus treated with the DPP-4 
inhibitor sitagliptin displayed reduced aggregation in vitro.12 
A later study showed increased platelet aggregation in 
Glp1r-deficient mice, along with increased cAMP-mediated 
signaling in platelets stimulated with the GLP-1R agonist 
exendin-4.13 Furthermore, the GLP-1R agonist exenatide 
(with sequence similarity to exendin-4) was found to sup-
press aggregation responses of human and mouse platelets, 
paralleled by cAMP changes.14 Together, these observations 
supported the concept that the DPP-4-GLP-1R axis can 
regulate platelet functions. However, mechanistic insights 
how DPP-4 inhibition affects platelet properties in the con-
text of thrombus formation are still missing. Furthermore, 
albeit previous studies examined synthetic GLP-1R agonists 
(exendin-4 and exenatide, with only ≈50% sequence iden-
tity to native GLP-115), the regulation of platelet responses 
by native, uncleaved GLP-1 has not been investigated. Con-
sidering that ex vivo measurements of collagen-dependent 
thrombus formation under flow can be used as a validated 
proxy measure of arterial thrombosis in vivo,16 the present 
study used a whole blood microfluidics assay in a multipa-
rameter setting17 for detailed assessment of alterations in 
thrombus formation triggered by (1) DPP-4 inhibition and 
(2) native uncleaved versus DPP-4-cleaved GLP-1 forms.
MATERIALS AND METHODS
The authors declare that all supporting data are available within 
the article and the online-only Data Supplement files. A detailed 
version of Materials and Methods is available in the online-only 
Data Supplement.
Major Resources
Please see the Major Resources Table in the online-only Data 
Supplement.
Human Blood and Platelet Isolation
Experiments were approved by the local Medical Ethics Committees 
(EK191/14, University Hospital Aachen; and METC 10-3-023, 
Maastricht University). Human blood was drawn from healthy vol-
unteers after full informed consent, conform the Declaration of 
Helsinki. Blood was collected into 3.2% trisodium citrate; the first 
3 mL were discarded. Platelet-rich plasma (PRP) was obtained by 
centrifuging citrate anticoagulated blood at 250g for 15 minutes, 
and platelet-free plasma was collected by centrifuging twice at 
2150g for 10 minutes. To obtain washed platelets, PRP was centri-
fuged at 2200g for 2 minutes, the remaining pellet was washed with 
HEPES (4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid) buf-
fer (10 mmol/L HEPES, 136 mmol/L NaCl, 2.7 mmol/L KCl, 2 
mmol/L MgCl2, 1 mg/mL glucose, 1 mg/mL bovine serum albumin, 
pH 6.6), before washed platelets were suspended into HEPES buf-
fer pH 7.45. Platelet count was determined using a Sysmex XN-350 
hematology analyzer (Sysmex, Chuo-ku Kobe, Japan).
Mouse Blood for Platelet Studies
All animal experiments were approved by the local authorities 
(Landesamt für Natur, Umwelt und Verbraucherschutz Nordrhein-
Westfalen, Germany, approval number 81-02.04.2017.A413; and 
by the Landesuntersuchungsamt Koblenz, approval numbers 
G17-1-050 and G14-1-039) and complied with the German ani-
mal protection law. To study platelet activation, blood was obtained 
from mice with deficiencies in Glp1r or Dpp4,18,19 both on a 
C57BL/6J genetic background. DPP-4 knockout mice (Dpp4−/−) 
were bred in Mainz or Aachen; they were originally a kind gift 
of Dirk Reinhold (Otto-von-Guericke-University Magdeburg, 
Magdeburg, Germany) and generated by Didier Marguet (Centre 
Nonstandard Abbreviations and Acronyms
CRP-XL collagen-related peptide
DPP-4 dipeptidyl peptidase 4
FITC fluorescein isothiocyanate
GLP-1 glucagon-like peptide 1
GLP-1R glucagon-like peptide 1 receptor
PRP platelet-rich plasma
SAC surface area coverage
VWF von Willebrand factor
Highlights
• Inhibition of DPP-4 (dipeptidyl peptidase 4) enzyme 
activity in vivo, genetic deficiency of DPP-4 and 
increased levels of native GLP-1(glucagon-like pep-
tide 1[7-36]) suppress collagen-mediated thrombus 
formation under physiological flow conditions.
• Suppression of platelet responsiveness by native 
GLP-1(7-36) requires flow conditions but occurs 
independently of plasma factors and without a main 
relevance of GLP-1R on platelets.
• These findings contribute a mechanistic explana-
tion for the cardiovascular benefit of true GLP-1(7-
36)–mimetics but not of exendin-based GLP-1R 
agonists.
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d’Immunologie de Marseille-Luminy, Marseille, France).18 GLP-1R 
knockout mice (Glp1r−/−) were bred in Mainz; they were originally 
obtained from Charles River (Sulzfeld, Germany) and generated 
by Daniel Drucker (Mt Sinai Hospital, Toronto, Canada).19 Wild-
type control mice of the same background came from the same 
breeding program. Because initial characterization of DPP-4-
knockout animals did not reveal differences between sexes,18 we 
have conducted our experiments in mixed-sex, using age- and 
sex-matched littermates between experimental groups. All exper-
iments were performed using age- and sex-matched littermates. 
Where indicated, Dpp4−/− mice were fed a normal laboratory diet 
(Sniff PS R/M-H mod.) supplemented with linagliptin (83 mg/
kg diet) or sitagliptin (280 mg/kg diet) for 5 days. The mice were 
anesthetized by an intraperitoneal injection of 100 mg/kg per 
body weight ketamine and 10 mg/kg xylazine. Blood from mice 
was collected into 40 µmol/L PPACK, 5 U/mL heparin and 40 
U/mL fragmin or trisodium citrate.
DPP Activity Measurements
DPP-4 activity was measured in lysates and releasates from stim-
ulated human platelets. Therefore, washed platelets (1×107/mL) 
were stimulated with thrombin (1 U/mL), ionomycin (10 µmol/L), 
or CRP-XL (collagen-related peptide; 5 µg/mL) in the presence 
of 2 mmol/L CaCl2 for 45 minutes at 37°C. As a negative con-
trol, unstimulated platelets were treated with prostacyclin (0.1 
µg/mL) in the presence of 2 mmol/L CaCl2. In all cases, platelet 
releasates and lysates of pelleted platelets were analyzed. The 
pelleted platelets (1×106) were lysed with 360 µL cell lysis buffer, 
as described.20 DPP activity was measured using the DPP-IV-
Glo protease assay (Promega) according to the manufacturer’s 
instructions; per test 25 µL releasate or lysate was used plus 25 
µL assay reagent. The activity of DPP-4 plus that of its closest 
family members DPP-8 and DPP-9 (containing similar cleavage 
recognition motif and pH optimum) contribute to the luminescent 
read out in this assay; this is referred to as DPP-4-like activ-
ity. Specific quantification of DPP-4 or DPP-8/9 activities was 
performed by addition of the DPP-8/9 inhibitor 1G244 or the 
DPP-4 inhibitor sitagliptin, respectively, at final concentrations of 
7 µmol/L in the assay (30 minutes treatments). Measurements 
gave total DPP-4-like activity as well as specific DPP-4 and 
DPP-8/9 activity in platelets and platelet-free plasma.21
Whole Blood Thrombus Formation
An established whole blood microfluidics assay in a multiparam-
eter setting was applied for a detailed assessment of alterations 
in thrombus formation under physiological flow conditions, as 
described.17 Glass coverslips were coated with 2 µL microspots of 
collagen type I (100 µg/mL) and collagen type III (100 µg/mL) 
and were subsequently blocked with 1% bovine serum albumin. 
Citrated mouse blood was recalcified (3.75 mmol/L MgCl2, 7.5 
mmol/L CaCl2) in the presence of PPACK (40 µmol/L) and sub-
sequently, perfused over the coated surfaces for 3.5 minutes at 
a wall-shear rate of 1000/s. Mouse blood collected into PPACK 
anticoagulant medium did not require recalcification. Where indi-
cated, blood samples were pretreated with iloprost (0.55 µmol/L) 
or exendin-9 (10 nmol/L) for 30 minutes; or alternatively with sita-
gliptin (7 µmol/L) in combination with GLP-1(7-36) (50 nmol/L) or 
vehicle for 10 minutes before perfusion. Thrombi formed after 3.5 
minutes of flow were directly postlabeled with a mixture of fluores-
cein isothiocyanate (FITC)-conjugated anti-P-selectin mAb (1:40), 
PE-labeled JON/A mAb (1:20; to analyze integrin activation) and 
AF647-annexin A5 (1:200; to analyze exposure of phosphatidyl-
serine) in modified Tyrode’s buffer (136 mmol/L NaCl, 2.7 mmol/L 
KCl, 0.42 mmol/L NaH2PO4, 5 mmol/L HEPES, 2 mmol/L MgCl2, 
1 mg/mL glucose, and 1 mg/mL bovine serum albumin, pH 7.45) 
containing CaCl2 (2 mmol/L) and heparin (1 U/mL).
For formation of human platelet thrombi, citrated blood 
from healthy subjects was recalcified (3.75 mmol/L MgCl2; 7.5 
mmol/L CaCl2) in the presence of PPACK (40 µmol/L) and 
perfused over collagen I surface at given wall-shear rates (6 
minutes at 150/s; 3.5 minutes at 1000/s or 1700/s).22 Where 
indicated, blood samples were preincubated with sitagliptin for 
10 minutes (7 µmol/L) plus GLP-1(7-36) (50 nmol/L), GLP-
1(9-36) (50 nmol/L) or vehicle, and coperfused with 2-methyl-
thioadenosine diphosphate (1 µmol/L, f.c.). Human thrombi 
formed on the surfaces were stained with AF647-conjugated 
anti-P-selectin mAb (2 µg/mL), FITC-labeled anti-fibrinogen 
mAb (1:100; to quantify fibrinogen binding as read out for inte-
grin activation), and AF568-annexin A5 (1:200) in HEPES buf-
fer (10 mmol/L HEPES, 136 mmol/L NaCl, 2.7 mmol/L KCl, 2 
mmol/L MgCl2, 1 mg/mL glucose, and 1 mg/mL bovine serum 
albumin) containing CaCl2 (2 mmol/L) and heparin (1 U/mL).
Per flow run, series of representative brightfield and fluores-
cence images were captured for analysis of surface area cover-
age (SAC) by adhered platelets (platelet SAC) as well as for 
analysis of platelet activation markers (phosphatidylserine expo-
sure, P-selectin expression, integrin activation) using scripts 
written in Fiji software, as described.17,23 Furthermore, based on 
the brightfield images of adhered platelets, effects on platelet 
aggregation and thrombus formation were assessed by quanti-
fying the multilayer SAC as well as by determining a morpholog-
ical score, contraction score, and multilayer score. These scores 
were determined by visual inspection of the platelet features per 
microspot in comparison to preset reference images, using the 
following criteria17: morphological score (range, 0–5): 0, no or 
hardly any adhered platelets; 1, multiple single-adhered plate-
lets; 2, extensive coverage of single-adhered platelets; 3, small 
platelet aggregates; 4, intermediate platelet aggregates; and 5, 
thrombi with large-size platelet aggregates. Contraction score 
(range, 0–3): 0, no contraction; 3, close contraction. Multilayer 
score (range, 0–3): 0, no platelet layers; 3, multilayered aggre-
gates.24 Observers were blinded to the experimental condition.
For quantification of thrombus volume and height, blood 
samples were incubated with sitagliptin (7 µmol/L) in com-
bination with vehicle, GLP-1(7-36) (50 nmol/L) or GLP-1(9-
36) (50 nmol/L) for 10 minutes at room temperature. The 
membrane probe DiOC6 (0.5 µg/mL) was added to the blood 
samples before recalcification to label the platelets. After blood 
perfusion for 3.5 minutes at 1000/s, z-stacks of confocal 
fluorescence images were recorded with a spacing of 0.5 µm 
using a fast line-scanning Zeiss LSM7 system (Oberkochen, 
Germany), equipped with a 63× oil immersion objective.
Reconstituted Human Blood
For reconstitution of human blood, platelets were isolated, and 
platelet count was adjusted to 250×106/mL with HEPES buf-
fer pH 7.45. Washed erythrocytes were obtained by centrifuga-
tion of citrate anticoagulated blood at 250g for 15 minutes. For 
the removal of remaining plasma and platelets, erythrocytes 
were washed 2× with HEPES buffer pH 7.45.25 Reconstituted 
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blood (washed platelets [250×106/mL], washed erythrocytes 
[Hct=40%], 100 µg/mL human fibrinogen, 7.5 µg/mL AF546-
conjugated human fibrinogen, 2 mmol/L CaCl2, and 2 mmol/L 
MgCl2) was incubated with vehicle or indicated peptide (50 
nmol/L) in the presence of 7 µmol/L sitagliptin for 10 min-
utes. Glass coverslips were coated with 2 µL microspots of 
collagen type I (100 µg/mL) plus VWF (von Willebrand factor; 
50 µg/mL). Whole blood thrombus formation was performed 
as described above.
Light Transmission Aggregometry
Washed platelets (25×107/mL, 2 mmol/L CaCl2) or PRP were 
preincubated with sitagliptin (7 µmol/L) in combination with 
GLP-1(7-36) (50 nmol/L) or vehicle for 10 minutes at room 
temperature. Platelet aggregation was induced by a submaxi-
mal concentration of collagen type I and measured under con-
stant stirring at 37°C using a lumi-aggregometer (Chronolog 
Corporation; Havertown, PA).
Flow Cytometry
Human washed platelets (50×106/mL) and citrate anticoagu-
lated whole blood were treated with vehicle, 50 nmol/L GLP-
1(7-36) or 50 nmol/L GLP-1(9-36) in the presence of 7 µmol/L 
sitagliptin for 10 minutes. Subsequently, platelet activation was 
induced by 1 µg/mL CRP-XL. Activated platelets were labeled 
with FITC-labeled PAC-1(1:20 [washed platelets], 1:25 [whole 
blood]; to analyze integrin activation), PE-labeled P-selectin 
(1:40 [washed platelets], 1:25 [whole blood]) and AF-647 
labeled TLT-1 (TREM-like transcript 1; 1:25 [washed plate-
lets], 1:25 [whole blood]). Integrin αIIbβ3 activation, P-selectin, 
and TLT-1 expression were assessed using flow cytometry (BD 
Canto II). Data were analyzed using FlowJo software 10.6.1.
Statistics and Heat Mapping
After testing for normality and equal variance, data were 
analyzed as appropriate, using a one-sample t test with a 
Bonferroni correction for multiple comparisons, a Wilcoxon 
matched-pairs signed-rank test (nonparametric) with a 
Bonferroni correction for multiple comparisons, a one-way 
ANOVA with Dunnett multiple comparisons test or a two-way 
ANOVA with a Sidak multiple comparisons test. GraphPad 
Prism 6 Software was used throughout. P<0.05 were consid-
ered to be statistically significant.
Mean values of whole blood thrombus formation assays 
were averaged per parameter and per surface and scaled over 
a range from 0 to 10 per parameter. Univariate scaled heat-
maps were generated using the program R.17,26 Where indicated, 
data were transformed into subtraction heatmaps to compare 
to control conditions. Filtering of the subtraction arrays was 
according to conventional large effect sizes (Cohen’s d ≥0.8).27
RESULTS
Platelets Harbor High DPP-8/9 and Minimal 
DPP-4 Activity Compared to Plasma
We first determined DPP-4-like enzyme activity in 
platelet lysates and in releasates of activated platelets 
using the DPP-IV-Glo protease assay. This assay 
quantifies DPP-4-like N-terminal X-Pro dipeptide 
cleavage at a defined pH, which can be caused by 
DPP-4 or by the related DPP-4 activity and/or struc-
ture homolog (DASH) proteases, DPP-8 and DPP-9. 
As assessed in lysates as well as platelet releasates, 
platelet stimulation with thrombin, ionomycin or CRP-
XL could not trigger an increase in DPP-4-like activity 
(Figure 1A and 1B). To identify the active DPP enzyme, 
enzymatic measurements were repeated in the pres-
ence of sitagliptin (to block DPP-4) or 1G244 inhibitor 
(to block DPP-8/DPP-9) at concentrations optimized 
for enzyme selectivity (Figure IA and IB in the online-
only Data Supplement). This analysis revealed that the 
DPP activity in lysed platelets was because of DPP-
8/9 and not to DPP-4 (Figure 1A). In platelet releas-
ates, DPP-4-like activity was because of DPP-4, with 
only minor levels of DPP-8/9 activity measurable 
(Figure 1B). Absolute quantification demonstrated in 
washed platelets a DPP-8/9 activity of 82±6 mU/g 
protein, whereas the DPP-4 activity was limited to 3±1 
mU/g (Figure 1C). In contrast, platelet-free plasma 
revealed a high enzyme activity of DPP-4 (113±16 
mU/g) but no enzymatically active DPP-8/9.
Together, these results indicate that the DPP-4-like 
activity in platelets derives from DPP-8/9 and not DPP-
4, whereas platelet-free plasma displays high DPP-4 but 
no DPP-8/9 activity.
Deficiency or Inhibition of DPP-4 in Mice 
Suppresses Thrombus Formation Under Flow 
Without a Main Role for Platelet GLP-1R
To examine the effect of DPP-4 on platelet responses, 
we studied thrombus formation in perfused whole blood 
from Dpp4−/− mice in comparison to corresponding 
wild-type mice. In whole blood samples perfused over 
collagen I at arterial wall-shear rate ex vivo, platelet acti-
vation and characteristics of thrombus formation were 
assessed by multicolor microscopy (Figure 2A). Based 
on the microscopy images, a subtraction heatmap con-
sisting of scaled values of 8 parameters of thrombus 
formation was generated and filtered for large effect 
sizes (Cohen’s d ≥0.8). This revealed a reduction in 
thrombus formation on DPP-4 deficiency, as apparent 
from the observed reductions for thrombus morphology 
(4.51±0.41 versus 3.71±0.63) and contraction scores 
(2.32±0.56 versus 1.98±0.70; Figure 2B, Table III in 
the online-only Data Supplement). Along the same line, 
treating wild-type mice for 5 days with the DPP-4 inhibi-
tors linagliptin and sitagliptin, markedly reduced platelet 
responses under flow, as demonstrated by reductions 
in thrombus morphology, contraction, and multilayer 
scores, as well as by reduced platelet deposition (quan-
tified as platelet SAC and platelet multilayer SAC; Fig-
ure 2C, Table III in the online-only Data Supplement). 
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Platelet counts were not affected by DPP-4 deficiency 
or inhibition and neither were white nor red blood cell 
counts (Table VI in the online-only Data Supplement). 
Treating Dpp4−/− mice with linagliptin or sitagliptin could 
not further reduce responses of platelets under flow 
(Figure 2C, Table III in the online-only Data Supple-
ment), indicating that the inhibitory effects of linagliptin 
and sitagliptin on the thrombotic process are mediated 
by interference with DPP-4.
As previous research suggested that GLP-1R activa-
tion reduces platelet activation at least partially by raising 
cAMP levels,13 we also assessed thrombus formation in 
the presence of the stable prostacyclin analog iloprost, 
which elevates platelet cAMP levels via Gs stimulation.28 
Compared to DPP-4 deficiency, iloprost pretreatment led 
to a more severe reduction in essentially all parameters 
of thrombus formation. Upon additional DPP-4 defi-
ciency, we observed a minor further decrease in plate-
let adhesion and integrin activation on collagen I (Figure 
IIB through IID and Tables III and IV in the online-only 
Data Supplement). DPP-4 deficiency did not alter throm-
bus formation on a less activating collagen III surface 
in either the absence or presence of iloprost (Figure IIA 
through IIC and Table IV in the online-only Data Sup-
plement). Together, these results indicate that genetic 
absence, as well as inhibition of DPP-4, leads to a reduc-
tion in collagen I-dependent thrombus formation under 
flow, although to a lesser degree than caused by cAMP 
elevation with iloprost.
With the GLP-1R agonist exendin-4 previously 
shown to reduce platelet aggregation,13,14 we next 
investigated whether GLP-R1 signaling may explain 
the observed effects on platelet responses in DPP-4 
knockout mice. Analysis of Glp1r expression in highly 
pure, isolated platelets by droplet digital polymerase 
chain reaction analysis revealed low but detectable 
levels of Glp1r mRNA transcripts in mouse platelets 
(Figure IIIA through IIIC in the online-only Data Supple-
ment). Thus, we assessed whether GLP-1R blocking 
with exendin-9 could increase platelet responsive-
ness in Dpp4−/− mice. In flow assays over collagen I, 
blood from Dpp4−/− mice showed comparable platelet 
deposition (37.67±8.28 [Dpp4−/−] versus 43.03±15.02 
[Dpp4−/− + exendin-9], P=0.29, n=10–13) and multi-
layer thrombus formation (13.67±6.27 [Dpp4−/−] versus 
16.86±11.16 [Dpp4−/− + exendin-9], P=0.39, n=10–
13; mean±SD) in the absence versus presence of exen-
din-9. Also, adding exendin-9 to Dpp4−/− blood did not 
alter parameters of thrombus morphology (3.79±0.68 
[Dpp4−/−] versus 4.21±0.83 [Dpp4−/− + exendin-9], 
P=0.19, n=11–13), contraction (1.86±0.78 [Dpp4−/−] 
versus 2.21±0.77 [Dpp4−/− + exendin-9], P=0.20, 
n=12–13) and multilayer scores (1.89±0.61 [Dpp4−/−] 
versus 2.17±0.85 [Dpp4−/− + exendin-9], P=0.35, 
n=11–13). Furthermore, differently than observed for 
Dpp4−/− mice, GLP-1R deficiency did not alter platelet 
Figure 1. High DPP (dipeptidyl peptidase)-8/9 activity in 
platelets and high DPP-4 activity in plasma. 
A and B, Washed human platelets (1×107/mL) were stimulated with 
thrombin (1 U/mL), ionomycin (10 µmol/L), or CRP-XL (collagen-
related peptide; 5 µg/mL) at 37°C for 45 minutes, as indicated. 
As a negative control, platelets were treated with prostacyclin 
(0.1 µg/mL). DPP-4-like activity, specific DPP-4 activity (in the 
presence of DPP-8/9 inhibitor 1G244, 7 µmol/L), and DPP-8/9 
activity (in presence of DPP-4 inhibitor sitagliptin, 7 µmol/L). Activity 
measurement in (A) platelet lysates and (B) platelet releasates using 
the DPP-IV-Glo protease assay. DPP activity was expressed relative 
to total DPP-4-like activity in prostacyclin-treated platelets (ctrl), 
and displayed as medians with interquartile range (IQR); n=6–8. 
Wilcoxon matched-pairs signed-rank test (stimulated vs ctrl), with 
Bonferroni correction for multiple comparisons. C, DPP-4-like activity 
and specific DPP-8/9 and DPP-4 activities in lysates from resting 
platelets and in platelet-free plasmas, quantified as described21; 
n=5–6. Data are displayed as means ± SD; two-way ANOVA with 
Sidak multiple comparisons test, ***P<0.001.
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adhesion, aggregation, activation, or thrombus structure 
parameters on collagen I and only induced an increase 
in phosphatidylserine exposure (Figure IVA through IVC 
and Tables III and IV in the online-only Data Supple-
ment). On a collagen III surface, on which we had not 
observed effects of DPP-4 deficiency (Figure II and 
Table IV in the online-only Data Supplement), GLP-1R 
deficiency increased parameters of thrombus mor-
phology, contraction, and multilayer score (Figure IVA 
through IVC and Table IV in the online-only Data Sup-
plement). Whereas the addition of GLP-1(7-36) did not 
affect thrombus formation in wild-type mice under the 
investigated conditions, it still could annul the effects 
of GLP-1R deficiency on collagen III induced throm-
bus formation (Figure IVA through IVC and Table IV in 
the online-only Data Supplement), indicating GLP-1 to 
reduce platelet responses independently of GLP-1R.
In summary, these data indicate that deficiency or 
blocking DPP-4 suppresses thrombus formation under 
flow in mouse blood without a main relevance of GLP-1R 
on platelets.
Native GLP-1(7-36) but Not DPP-4-Cleaved 
GLP-1(9-36) Reduces Platelet Aggregation in 
Human Whole Blood Under Flow
Next, we tested the effects of a short-term treatment of 
human blood samples with the DPP-4 inhibitor sitagliptin. 
Sitagliptin did not affect collagen I-induced thrombus 
formation under flow (Figure V in the online-only Data 
Supplement), while it efficiently inhibited DPP-4 (data 
not shown). These results hence raised the hypothesis 
that the reduced thrombus formation, observed by in vivo 
DPP-4 inhibition in mice, is due to an accumulation of 
noncleaved over cleaved DPP-4 substrates, rather than 
by a direct DPP-4-mediated enzymatic effect on the 
thrombus formation parameters.
Given that the clinically applied DPP-4 inhibitors 
increase the plasma ratio of native GLP-1(7-36) over 
DPP-4-cleaved GLP-1(9-36), we directly compared the 
effects of GLP-1(7-36) versus GLP-1(9-36) peptides on 
human thrombus formation under a variety of flow con-
ditions, that is, low (venous), intermediate (large arterial), 
Figure 2. Murine DPP-4 (dipeptidyl peptidase 4) deficiency impairs thrombus formation under flow.
Blood from Dpp4−/− or wild-type control mice was perfused over collagen I microspots at 1000/s. Where indicated, mice were fed for 5 d a 
normal laboratory diet supplemented with linagliptin or sitagliptin. Thrombi formed were poststained with fluorescein isothiocyanate (FITC)-
labeled anti-P-selectin mAb (secretion), PE-labeled JON/A mAb (integrin activation) and AF647-annexin A5 (phosphatidylserine [PS] exposure). 
A, Representative brightfield and fluorescence images. Scale bar =20 µm. B, Subtraction heatmap of scaled values, compared to Dpp4+/+, 
filtered for differences with large effect size (Cohen’s d ≥0.8); n=23–26. C, Subtraction heatmap of scaled values, compared to wild type 
without treatment, filtered for differences with large effect size (Cohen’s d ≥0.8); n=6–13. SAC indicates surface area coverage.
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or high (small arterial) wall-shear rates. The heatmap of 
GLP-1(7-36) and GLP-1(9-36)-mediated effects on 
parameters of thrombus formation, obtained from series of 
microscopy images, indicated a substantial overall reduc-
tion of thrombus formation by GLP-1(7-36) under flow. 
Notably, this reduction was seen at all shear-flow con-
ditions, from low (150/s) and intermediate (1000/s) to 
high (1700/s; Figure 3A, Figure VI and Table V in the 
online-only Data Supplement). For quantification, subtrac-
tion heatmaps were generated in which the changes were 
filtered for large effect sizes (Cohen’s d ≥0.8). This analy-
sis revealed reductions especially in aggregation-related 
parameters (multilayer thrombus SAC, multilayer, morpho-
logical, and contraction scores), whereas the typical plate-
let activation markers P-selectin and activated integrin 
(Figure 3B, Table V in the online-only Data Supplement), 
as well as TLT-129 (data not shown), were less affected.
In addition, we investigated the effects of GLP-1(7-36) 
on thrombus formation on co-infusion with stable ADP. 
This resulted in a clear reduction in platelet deposition 
(30.17±8.69% [control] versus 25.25±14.38% GLP-
1(7-36)) as well as platelet aggregation (21.35±4.06% 
[control] versus 8.76±3.54% [GLP-1(7-36)]; Figure 3C 
and 3D, Figure VIC and Table V in the online-only Data 
Supplement). In sharp contrast, equal concentrations of 
the DPP-4-cleaved GLP-1(9-36) were unable to reduce 
thrombus formation under flow but instead triggered 
minor increases in adhesion-related parameters (multi-
layer SAC at 150/s; platelet SAC at 1000/s with ADP 
co-infusion; Figure 3B and 3D, Table V in the online-only 
Data Supplement).
In summary, native GLP-1(7-36), but not DPP-4-
cleaved GLP-1(9-36), reduces platelet aggregation in 
human whole blood under flow.
Platelet-Inhibitory Effect of Native GLP-1(7-
36) Requires Flow but Not Plasma Factors or 
Leukocytes
To assess the effects of GLP-1 in further detail, we exam-
ined aggregation responses of slowly stirred suspensions 
of human platelets using light transmission aggregometry. 
Strikingly, and in contrast to the clear GLP-1-mediated 
effects on whole blood thrombus formation, neither GLP-
1(7-36) nor GLP-1(9-36) did affect collagen-induced 
platelet aggregation responses in the stirred suspensions 
(fold change for GLP-1(7-36): 1.13±0.13 and 0.94±0.04 
in washed platelets and PRP, respectively, versus 
0.74±0.03 in whole blood; Figure 4). Furthermore, neither 
GLP-1(7-36) nor GLP-1(9-36) affected CRP-XL-induced 
platelet activation markers, as quantified by flow cytomet-
ric analysis of integrin αIIbβ3 activation, when assessed in 
washed platelets or in whole blood (Figure 4, Figure VIIA 
and VIIB in the online-only Data Supplement). Similarly, the 
CRP-XL-induced expression of P-selectin and TLT-1 on 
platelets was unaltered in the presence of GLP-1(7-36) 
or GLP-1(9-36) in either washed platelets or whole blood 
(Figure VIIA and VIIB in the online-only Data Supplement). 
Along the same line, neither GLP-1(7-36) nor GLP-1(9-
36) altered the phosphorylation state of AKT (AKT ser-
ine/threonine kinase), ERK (extracellular signal-regulated 
kinase) 1/2, or SYK (spleen-associated tyrosine kinase) in 
human platelets on thrombin, ADP, or CRP-XL stimulation 
(Figure VIII in the online-only Data Supplement). However, 
GLP-1(7-36) still reduced thrombus size and contraction 
under flow even in the absence of plasma factors, as ana-
lyzed using reconstituted blood samples containing only 
washed platelets, erythrocytes, and fibrinogen (Figure 5). 
Combined, these results underline that GLP-1(7-36) 
depends on flow conditions but does not require plasma 
factors for its inhibitory effect on platelets.
Triggered by these GLP-mediated effects on human 
platelet responsiveness, we analyzed GLP1R expres-
sion in preparations of highly pure, human platelets. No 
GLP1R transcripts could be detected by droplet digital 
polymerase chain reaction in human platelets, despite 
GLP1R expression in human pancreas as positive control 
(Figure IIID through IIIF in the online-only Data Supple-
ment). Thus, these data indicate that platelet GLP-1R 
does not play a main role in the GLP-mediated effects 
observed under flow.
Recorded microscopic images from collagen I sur-
faces suggested that GLP-1(7-36) suppressed the 
3-dimensional buildup of thrombi under flow condi-
tions. To confirm this, we quantified thrombus volumes 
by recording confocal z-stacks of thrombi consisting 
of DiOC6-labeled platelets. Markedly, the addition of 
GLP-1(7-36) reduced thrombus volume and height by 
32±8% and 23±9%, respectively (mean±SD; Figure 6A 
and 6B), with an overall smaller thrombus area at each 
confocal plane (Figure 6C and 6D). In line with previous 
observations, the DPP-4-cleaved GLP-1(9-36) did not 
affect thrombus volume or height (Figure 6).
Altogether, these results reveal a mechanism in 
which, in vivo, plasma-derived DPP-4 activity promotes 
thrombus formation by cleaving native GLP-1(7-36) to 
GLP-1(9-36). The cleaved GLP-1(9-36) can no lon-
ger suppress thrombus formation in whole blood. In 
the absence of DPP-4 activity—either by genetic defi-
ciency or by long-term inhibitory treatment—the native, 
uncleaved GLP-1 accumulates in the blood and con-
tinues to suppress the flow-dependent formation of 
thrombi, independent of plasma factors and without a 
main relevance of GLP-1R on platelets.
DISCUSSION
In this article, we provide novel clarification for the anti-
thrombotic effect of DPP-4 inhibition, acting through sup-
pressed cleavage of GLP-1(7-36) to GLP-1(9-36). Our 
findings demonstrate that inhibition or genetic deficiency 
of DPP-4 in mice results in reduced thrombus formation 
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Figure 3. GLP-1 (glucagon-like peptide 1 [7-36]) suppresses human whole blood thrombus formation regardless of wall-shear rate.
Human blood was preincubated with GLP-1(7-36) (50 nmol/L), GLP-1(9-36) (50 nmol/L) or vehicle control for 10 min. Sitagliptin (7 µmol/L) 
was present in all conditions. A and B, After recalcification, samples were perfused over collagen I microspots at indicated wall-shear rates. 
Thrombi formed were poststained for phosphatidylserine (PS) exposure, P-selectin expression, and integrin activation. A, Representative 
brightfield and fluorescence images at wall-shear rate of 1000/s. B, Subtraction heatmap of scaled parameter values, compared to means of 
controls; filtered for differences with large effect size (Cohen’s ≥0.8); n=12 for 1000/s; n=4 for 150/s and 1700/s. C and D, Blood samples 
were coperfused with 2-methylthioadenosine diphosphate (2MeADP; 1 µmol/L) over collagen 1000/s. C, Representative brightfield and 
fluorescence images (n=4). D, Subtraction heatmap of scaled values, compared to means of controls; filtered for large effect size as above. 
Scale bars =20 µm. Figure VI in the online-only Data Supplement shows representative images for thrombus formation at shear rates 150/s 
and 1700/s. SAC indicates surface area coverage.
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under flow. This regulation could be confirmed in human 
whole blood samples by the native peptide GLP-1(7-36), 
that is, a main substrate of DPP-4. In this case, the eleva-
tion of GLP-1(7-36) but not of the DPP-4-cleaved GLP-
1(9-36) resulted in the formation of smaller and less 
contracted thrombi formed on collagen, at both venous 
and arterial flow conditions. The inhibitory effect of GLP-
1(7-36) on platelet responsiveness required flow condi-
tions, but not plasma factors, leukocytes or GLP-1R on 
platelets. In contrast to native GLP-1(7-36), the DPP-4-
cleaved form GLP-1(9-36) triggered minor increases in 
platelet responsiveness in flowed whole blood.
Several earlier studies have shown that DPP-4 is 
expressed by different cell types within the blood and 
vasculature, including T lymphocytes and endothelial 
cells,3,30 but platelet DPP-4-like activity had not been 
studied in detail before. Here, we indicate that the DPP-
4-like activity, measurable in platelets, is primarily due 
to the DASH proteases DPP-8/9 and not to DPP-4. 
These results are in line with recent data reporting that 
megakaryocytes and platelets do not harbor detectable 
DPP-4 enzyme activity14 and express the DPP-4-family 
members DPP-2, DPP-3 and DPP-9 but not DPP-4 
according to proteomics analyses.31 Accordingly, residual 
DPP-4 activity detected in platelet releasate may have 
been derived from plasma remnants, for example, pres-
ent in the open canicular system of platelets. Further-
more, we could confirm that plasma reveals high DPP-4 
activity.
When DPP-4 activity was deficient in mice, either by 
long-term in vivo administration of linagliptin or sitagliptin 
or by genetic deficiency, we observed marked reductions 
in collagen I-dependent platelet responses under flow. 
In contrast, short-time DPP-4 inhibition did not influ-
ence whole blood thrombus formation, indicating that 
the platelet responds to the accumulation of uncleaved 
over cleaved DPP-4 substrates, rather than to the 
DPP-4 enzymatic activity per se. The observation that in 
vivo treatments with linagliptin or sitagliptin suppressed 
platelet responses in wild type but not in Dpp4−/− mice 
indicates that the inhibitory effects of these drugs are 
mediated through DPP-4 itself and not through off-target 
(non–DPP-4 related) effects. In line with this conclusion, 
a previous study revealed reduced endotoxemia-induced 
thrombosis in mice with a Dpp4 deficiency or treated 
with the DPP-4 inhibitor linagliptin.13
One of the best described DPP-4 substrates is 
GLP-1(7-36), which is cleaved by DPP-4 to GLP-1(9-
36).3 Physiologically, the half-life of GLP-1(7-36) is 
short (1.5–5 minutes).32 Accordingly, the stable, syn-
thetic GLP-1(7-36)-analog liraglutide (97% amino acid 
sequence identity to GLP-1[7-36]) and the peptide 
exenatide (a synthetic form of the GLP-1R agonist exen-
din-4, with 50% sequence identity to GLP-1(7-36)15) are 
of improved efficacy in the clinical therapy of hypergly-
cemia. As an alternative, DPP-4 inhibitors are clinically 
used to rise the endogenous levels of native, uncleaved 
GLP-1.33 In this article, we specifically focused on the 
platelet effects of the physiological, uncleaved versus 
DPP-4-cleaved GLP-1 peptides. In accordance with the 
phenotypes of DPP-4 deficiency and long-term in vivo 
DPP-4 inhibition, we could establish that increased levels 
of native GLP-1(7-36), but not of cleaved GLP-1(9-36), 
reduced whole blood thrombus formation under flow.
Our findings indicate that the largest effects of GLP-
1(7-36) supplementation are observed in the presence 
of shear flow. In flowed human blood, GLP-1(7-36) 
addition caused a markedly decreased thrombus vol-
ume and height. In contrast, the peptide was unable to 
reduce collagen-induced platelet aggregation in slowly 
stirred suspensions of washed platelets or PRP, and it 
did not affect platelet activation markers in flow cytom-
etry analyses of washed platelets or whole blood. In line 
with a report of Barale et al34 in which GLP-1(7-36) 
alone was unable to reduce collagen- or arachidonic 
acid-induced platelet aggregation, our data suggest that 
shear stress is needed to achieve the GLP-1(7-36)-
mediated platelet inhibition. As VWF-GPIb interactions 
Figure 4. GLP-1 (glucagon-like peptide 1 [7-36]) impairs 
collagen-induced platelet aggregation only in flowed 
whole blood.
Effect of GLP-1(7-36) (50 nmol/L) on (1) CRP-XL (collagen-related 
peptide)-induced platelet activation in washed platelets and whole 
blood as assessed by flow cytometry, analyzing integrin αIIbβ3 
activation and P-selectin expression (n=4) and on (2) collagen-
induced aggregate formation of washed platelets, platelet-rich 
plasma (PRP), and thrombus formation under flow, as indicated. 
Collagen-induced maximal aggregation of slowly stirred washed 
platelets (n=6) and PRP (n=14) was measured using a lumi-
aggregometer (light transmission aggregometry; LTA). Collagen-
dependent aggregate formation under flow at 1000/s was measured 
from overall aggregation parameters (multilayers, morphological, 
contraction, and multilayer scores; n=16). Present was 7 µmol/L 
sitagliptin in all conditions. Effects of GLP-1(7-36) are expressed as 
fold changes relative to vehicle control and are displayed as dot plots 
with indication of means ± SD. One-sample t test with Bonferroni 
correction for multiple comparisons. ***P<0.001; ns =not significant.
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are essential for high shear mediated platelet adhesion, 
we also examined a role of GLP-1(7-36) under condi-
tions of low/venous shear rate (150/s), where platelet 
adhesion and activation occurs independently of the 
VWF-GPIb axis.17 However, at all flow shear rates exam-
ined (150, 1000, and 1700/s), we observed a similar 
reduction of platelet aggregation parameters, strongly 
indicating that the effect of GLP-1(7-36) is independent 
of VWF. Literature further indicates that the GLP-1(7-
36) analog liraglutide also could not reduce collagen- or 
arachidonic acid-induced platelet aggregation in stirred 
PRP,34 whereas much higher levels (10–100 µmol/L) 
of the GLP-1(7-36) analog liraglutide were required to 
reduce ADP-induced platelet aggregation.13
Furthermore, our study revealed that the inhibitory 
effect of GLP-1(7-36) does not require plasma factors 
or leukocytes, as revealed by flow assays with reconsti-
tuted blood containing only washed platelets, washed 
erythrocytes and fibrinogen, and occurs without a main 
role for GLP-1R on platelets. In this context, expression 
of GLP-1R on platelets has been an intense matter of 
debate, in particularly also related to the lack of anti-
bodies with high sensitivity and verified specificity for 
human as well as mouse GLP-1R.18,35 On the one hand, 
Western blot and flow cytometer experiments have dem-
onstrated expression of GLP-1R on human platelets as 
well as on mouse platelets.13,14,34 On the other hand, 
proteomic analyses could not detect GLP-1R in human 
platelets31 or with only 2% sequence coverage,36 and 
also only low GLP1R mRNA levels were detected in the 
megakaryocyte platelet lineage.37 Using highly sensi-
tive droplet digital polymerase chain reaction, we could 
not detect GLP1R expression in human platelets, in line 
with transcriptomics data from the Blueprint Consortium 
(http://dcc.blueprint-epigenome.eu/#/home) revealing 
normalized expression values for GLP1R to be negligible 
in human platelets (log2(fpkm)=0.0005) compared to 
typical platelet receptors (eg, GPIbα: log2(fpkm)=9.26). 
Alongside, we could also detect only very low levels of 
GLP1R in human PBMCs, in line with transcriptomics 
data within the Human Protein Atlas database as well 
as provided by Schmiedel et al,38 revealing low GLP1R 
expression only in natural killer cells and specific T-cell 
subsets (≈0.2–5.2 transcripts per million). Our transcript 
analysis of mouse platelets did detect Glp1r mRNA. How-
ever, Dpp4−/− mice did not show significant differences 
Figure 5. Effects of GLP-1 (glucagon-like peptide 1 [7-36]) on thrombus formation under flow persist in absence of plasma 
factors and leukocytes.
Reconstituted human blood (containing washed platelets, erythrocytes, and fibrinogen) was incubated for 10 min with vehicle or 50 nmol/L 
GLP-1(7-36) in the presence of 7 µmol/L sitagliptin and perfused over a VWF (von Willebrand factor)-collagen type I surface at 1000/s. 
Thrombi were poststained for P-selectin expression and phosphatidylserine (PS) exposure. A, Representative brightfield and fluorescence 
images. B, Heatmap of univariate scaled (0–10) values for control or GLP-1(7-36) treatment. C, Subtraction heatmap of scaled parameter 
values, compared to means of control, filtered for differences with large effect size (Cohen’s d ≥0.8). Scale bar =20 µm. n=4. SAC indicates 
surface area coverage.
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Figure 6. GLP-1 (glucagon-like peptide 1 [7-36]) reduces thrombus size under flow.
Human blood was incubated for 10 min with vehicle, GLP-1(7-36) (50 nmol/L) or GLP-1(9-36) (50 nmol/L) in the presence of 7 µmol/L 
sitagliptin. Platelets in the blood were prelabeled with DiOC6. After flow perfusion at 1000/s, z-stacks were recorded of thrombi formed on 
collagen I microspots. A and B, Microscopy images analyzed for overall thrombus volume (A) and thrombus height (B). Data are displayed 
as means ± SD, n=4. One-way ANOVA with Dunnett multiple comparisons test vs vehicle; *P<0.05. C, Graphical representation of mean 
thrombus area (µm2) with SD (shaded area) for indicated distances from collagen surface. D, Representative z-stacks.
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in platelet deposition and aggregation in whole blood 
flow assays upon treatment with the GLP-1R antagonist 
exendin-9. Also, collagen I-induced thrombus formation 
under flow was unaltered in Glp1r−/− mice. Combined, 
these findings argue against a role of platelet GLP-
1R in GLP-1-mediated modulation of both human and 
mouse platelet responses and support the involvement 
of another receptor or receptor-independent mecha-
nism instead. This is in line with recent findings of Barale 
et al,34 who showed that GLP-1(7-36), as well as its 
synthetic homolog liraglutide, increased the inhibitory 
effects of the NO donor sodium nitroprusside on human 
platelet aggregation independently of GLP-1R. Also, 
renoprotective and immune-regulatory capacities were 
recently identified for native, intact GLP-1, which could 
not be fully recapitulated by GLP-1R agonists.39 Com-
bined, these studies, as well as our own article, reveal 
the increasingly appreciated importance of GLP-1R-in-
dependent actions of native, intact GLP-1. In relation to 
the antithrombotic effects previously observed for the 
GLP-1R agonist exenatide upon laser injury of the cre-
master arterioles in mice, a role for non-bone marrow-
derived cells was identified, with a potential involvement 
of the endothelium suggested.14
A recent international consensus article compared 
clinical trials on effects of DPP-4 inhibitors and GLP-
1R agonists on cardiovascular outcomes in patients with 
diabetes mellitus. A potential of cardiovascular protection 
was revealed for true homologs of native GLP-1 (liraglu-
tide and semaglutide, showing 97% and 94% sequence 
identity to GLP-1, respectively) and this independent of 
glucose control. In contrast, the GLP-1R agonists lixas-
enatide and exenatide, both sharing sequence similarity 
to exendin-4 (which is only ≈50% identical to GLP-115), 
were not, or only to a minor extent, associated with cardio-
protection.40 In this context, our data contribute a mecha-
nistic explanation for such protection, in that native, intact 
GLP-1 exerts platelet-inhibitory effects without a main 
relevance of GLP-1R on platelets. Especially in conditions 
of enhanced thrombus formation, such as in our study 
with ADP co-infusion, effects of increased GLP-1(7-36) 
over GLP-1(9-36) ratios were strikingly beneficial. In this 
context, native GLP-1(7-36) could be regarded as natural 
suppressor of platelet aggregation and thrombus growth 
under physiological flow conditions. Since overall, DPP-4 
inhibitors could not provide cardioprotection in clinical tri-
als,40 it can currently not be excluded that simultaneous 
stabilization of other DPP-4 substrates (eg, substance P 
or fibrin41,42) may interfere with GLP-1(7-36) mediated 
antiplatelet effects of DPP-4 inhibitors in patients, thus 
requiring further investigation.
In conclusion, our data provide novel evidence that 
DPP-4 inhibition and native GLP-1(7-36) can reduce 
whole blood thrombus formation at both venous and 
arterial flow shear rates, resulting in the formation of 
smaller and less contracted thrombi and this without a 
main relevance of GLP-1R on platelets. Furthermore, 
the crucial role of flow in GLP-1(7-36)–induced plate-
let effects observed in this study underlines the need to 
investigate thrombus formation in patients with diabetes 
mellitus treated with DPP-4 inhibitors and GLP-1 mimet-
ics specifically under physiological flow conditions.
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